However, therapeutic success has been achieved with general proteasome inhibitors (e.g., Bortezomib (Robak et al., 2015)) and indirect SCF inhibitors (e.g., MLN4924 (Swords et al., 2015)) for the treatment of lymphoma, myeloma and leukemia lending support to use of broad-spectrum inhibitors targeting SKP1 and/or the SCF complex (Skaar et al., 2014). Here, KITLG is linked to plasma cell myeloma.